Eidos Therapeutics

General Information


We are a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. We seek to treat this well-defined family of diseases by targeting them at their collective source by stabilizing TTR. TTR is a protein that occurs naturally in the form of a tetramer (a molecular structure consisting of four identical subunits, or monomers) and performs multiple beneficial roles, including the transport of essential hormones and vitamins.


Employees: 14
Founded: 2013
Contact Information
Address 101 Montgomery Street, Suite 2550, San Francisco, CA 94104, US
Phone Number (415) 887-1471
Web Address http://www.eidostx.com
View Prospectus: Eidos Therapeutics
Financial Information
Market Cap $608.8mil
Revenues $0 mil (last 12 months)
Net Income $-25.2 mil (last 12 months)
IPO Profile
Symbol EIDX
Exchange NASDAQ
Shares (millions): 6.3
Price range $17.00 - $17.00
Est. $ Volume $106.3 mil
Manager / Joint Managers J.P. Morgan/ BofA Merrill Lynch
CO-Managers Barclays
Expected To Trade: 6/20/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change